Table 3.

Mean cerebrospinal fluid levels of bound and unbound amyloid-beta (Aβ)40 and Aβ42 in Alzheimer’s disease patients treated with solanezumab

Solanezumab dose a	Mean CSF Aβ40, pg/mL b	Mean CSF Aβ42, pg/mL b
100 mg Q4W	625	0.0
100 mg QW	3,750	275
400 mg Q4W	5,625	233
400 mg QW	15,000	825

^aSolanezumab phase 2 MAD data [183]. ^bMean pg/mL levels of total bound and unbound Aβ40 and Aβ42 in cerebrospinal fluid (CSF) of treated patients, derived from Figures 3A and 3B reported by Farlow and colleagues [183]. Q4W, monthly dosing; QW, weekly dosing.